Is the Target therapy have a role in the treatment of Metastatic lung cancer in patients who is not fit for chemotherapy? Case Report

Introduction: Lung cancer is the most common cause of cancer death worldwide, with an estimated 1.6 million deaths each year. Approximately 85% of patients have a group of histological subtypes collectively known as NSCLC, of which lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the most common subtypes. Epidermal growth factor receptor (EGFR) and its mutations are found to have an important role in this cancer. Therefore, EGFR tyrosine kinase inhibitors (TKIs) can work effectively against NSCLC. Gefitinib and Erlotinib, which are a first generation TKI, and Afatinib, which is a second-generation TKI, are effective as a first-line therapy for advanced NSCLC. Case report: We describe here a case of a 52 years old Saudi female nonsmoker who was diagnosed as a case of adenocarcinoma of lung origin with brain and inguinal lymph node metastasis. The patient underwent urgent brain surgery, received palliative radiotherapy and due to his poor general condition, she cannot received chemotherapy and started on Erlotinb before molecular study results and fortunately, the patient get excellent clinical response with good radiological response.